Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that it has won the 2019 Ernst & Young’s (EY) “Born Global” award for ‘Region Est’, France. The award was received by Stephane van Rooijen (M.D. MBA), Chief Executive Officer of Dynacure, at the 2019 EY Entrepreneur of the Year awards ceremony on September 17. Dynacure is headquarted in Strasbourg, France, and has recently expanded its operations into the United States. Dynacure was selected by an independent judging panel made up of previous award winners, leading CEOs, investors and other regional business leaders.
“EY is proud to honor Dynacure with the prestigious “Born Global” award, reserved for truly innovative leading companies who conduct business on a global scale with no geographic boundaries,”said Franck Sebag, Partner Audit and Transaction Services EY France. “We believe Dynacure’s international presence and entrepreneurial spirit will create endless opportunities in the biotech industry and EY looks forward to helping them grow.”
Georges Gemayel (Chairman Dynacure) added, “Dynacure is developing the first antisense medicine to treat life-threatening rare disorders called centronuclear and myotubular myopathies (CNM). We are determined to provide patients with a therapeutic solution on a global scale and we thank EY for their recognition of our mission and purpose.”
About Entrepreneur Of The Year®
Entrepreneur Of The Year®, founded by EY, is the world’s most prestigious business awards program for entrepreneurs. The program makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global awards program of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries. www.ey.com/eoy
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders. The company maintains its headquarters in Strasbourg, France. Dynacure’s investors are Andera Partners, Bpifrance, IdInvest, Ionis Pharmaceuticals, Kurma Partners and Pontifax.
For more information, please visit www.dynacure.com.
Juniper Point – U.S. Investor & Media Relations
+1 858 366 3243